Background & Aims: This study evaluated the efficacy and safety of adalimumab, a fully
human, anti–tumor necrosis factor monoclonal antibody administered subcutaneously, in the …

Background: Adalimumab, a fully human tumor necrosis factor (TNF) antagonist, is an
effective treatment for patients with Crohn disease who are naive to the chimeric TNF …

Background: Adalimumab induced clinical remission after four weeks in patients with active
Crohn's disease in the CLASSIC I trial. Objective: To evaluate long term efficacy and safety …

BACKGROUND & AIMS: We investigated the efficacy of adalimumab for inducing and
maintaining mucosal healing in patients with Crohn's disease (CD). METHODS: A …

Objective: To evaluate the efficacy of adalimumab in the healing of draining fistulas in
patients with active Crohn's disease (CD). Design: A phase III, multicentre, randomised …

Background & Aims Patients with moderate to severe ileocolonic Crohn's disease (CD) who
received adalimumab induction and maintenance therapy had greater rates of mucosal …

OBJECTIVES We evaluated the effects of adalimumab maintenance therapy on health-
related quality of life (HRQOL) in patients with moderate to severe Crohn's disease …

Background & Aims Few studies have assessed the risk of malignancy from anti-tumor
necrosis factor monotherapy or combination therapy for Crohn's disease (CD). We …

Background and aims: We examined the impact of disease duration on clinical outcomes
and safety in a post hoc analysis of a remission maintenance trial with adalimumab in …

Background Mirikizumab is a humanized monoclonal antibody targeting interleukin 23p19
with demonstrated efficacy in psoriasis and ulcerative colitis. We investigated the safety and …